Assessment of changes in physiologic distribution of 68Ga-PSMA in normal tissues relative to tumor burden in patients undergoing PET/CT for prostate cancer
Öz
Purpose: This study aimed to evaluate changes in 68Ga-PSMA (Prostate-specific membrane antigen) uptake in normal tissues according to prostate cancer (PC) tumor burden, as assessed by PET/CT. Materials and Methods: This retrospective study included 213 consecutive patients with histologically confirmed PC who underwent 68Ga-PSMA PET/CT imaging. Based on PET/CT findings, patients were categorized into three groups according to 68Ga-PSMA expression: 1) PSMA-negative prostate cancer; 2) local disease: PSMA uptake limited to the prostate gland and/or pelvic region; 3) metastatic disease: presence of extrapelvic and/or distant PSMA-avid lesions. Results: Among the 213 patients, 68Ga-PSMA PET/CT imaging revealed normal PSMA distribution in 57 patients (26.8%), localized disease in 88 patients (41.3%), and metastatic involvement in 68 patients (31.9%). In the metastatic disease group, the mean SUVmax values were significantly lower in the lacrimal, parotid, and submandibular glands, as well as in the spleen, kidneys, and bowel, compared to the PSMA-negative prostate cancer and local disease groups. In contrast, prostate SUVmax was markedly higher in the metastatic group. Conclusion: This study demonstrates that 68Ga-PSMA uptake in normal tissues decreases with increasing metastatic tumor burden, particularly in salivary glands, kidneys, and lacrimal glands.
Anahtar Kelimeler
Prostate-specific membrane antigen, prostate cancer, 68Ga-PSMA PET/CT
Etik Beyan
Kaynakça
- Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol. 2020;77:403-17.
- Laudicella R, Bauckneht M, Burger IA, Cacciola A, Fanti S, Farolfi A et al. The role of PSMA-based radioligand therapy in hormone-sensitive prostate cancer. Eur J Nucl Med Mol Imaging. 2025;52:2723-35.
- Hofman MS, Lawrentschuk N, Francis RJ, M Williams, C Udovicich, I Vela, Thomas P et al. proPSMA Study Group Collaborators. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA):a prospective, randomised, multicentre study. Lancet. 2020;395:1208-16.
- Afshar-Oromieh A, Malcher A, Eder M et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486-95.
- Gafita A, Wang H, Robertson A, Armstrong WR, Zaum R, Weber M et al. Tumor sink effect in (68)Ga-PSMA-11 PET: myth or reality? J Nucl Med. 2022;63:226-32.
- Wolf P, Freudenberg N, Buhler P, Alt K, Schultze‐Seemann W, Wetterauer U et al. Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer. Prostate. 2010;70:562-9.
- Klein Nulent TJW, Valstar MH, de Keizer B, Willems SM, Smit LA, AlMamgani A et al. Physiologic distribution of PSMA-ligand in salivary glands and seromucous glands of the head and neck on PET/CT. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018;125:478-86.
- Gaertner FC, Halabi K, Ahmadzadehfar H, Kürpig S, Eppard E, Kotsikopoulos C et al. Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer. Oncotarget 2017;8:55094-103.
- Zamanian A, Rousseau É, Buteau FA et al. The tumour sink effect on 68Ga-PSMA-PET/CT in metastatic castration-resistant prostate cancer and its implications for PSMA-RPT. Cancer Imaging. 2025;25:91.
- Muniz M, Loprinzi CL, Orme JJ, Koch RM, Mahmoud AM, Kase AM et al. Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are going. Cancer Treat Rev. 2024:127:102748.
